The endothelin system in breast tumour–endothelial cell interactions

  • Tasnim Badat Department of Therapeutics and Medicines Management, University of KwaZulu- Natal
  • Julia Botha Department of Therapeutics and Medicines Management, University of KwaZulu- Natal
  • Strinivasen Naidoo Department of Therapeutics and Medicines Management, University of KwaZulu- Natal
Keywords: Cancer, Tumour-angiogenesis, Protein systems


The role of endothelin-1 (ET-1) and its receptors (ET-RA and ET-RB) in tumour development and progression involves complex interactions. ET-1, produced by tumours and associated cells like endothelial cells, functions in an autocrine and paracrine manner to promote tumour angiogenesis. Thus, we hypothesised that endothelin, released into the tumour milieu by both tumours and the tumour vasculature, would influence angiogenesis. Therefore, this preliminary study aimed to investigate changes in ET1, ET-RA and ET-RB in breast tumour and microvascular endothelial cultures when each cell type was exposed directly to the other (co-culture model) as well as to the conditioned-medium metabolites of the other (challenge model). ET-1 secretion was measured by an enzyme-linked immunosorbent assay and ET-1, ET-RA and ET-RB expression investigated by the linked streptavidin–biotin method. In challenge experiments, endothelial metabolites significantly increased secretion of breast tumour ET-1. Tumour metabolites promoted endothelial membrane projections with no effect on ET-1 secretion. ET-1 and its receptors were immunolocalised in both cell types, including in projections. Increasing cancer cell conditioned medium resulted in decreased endothelial ET-RA and increased ET-RB staining. Co-cultures demonstrated ET proteins in projections of both cell types as well as at heterogeneous contact points. The findings support a role for the endothelin system in endothelial cell and breast cancer cell invasion. It is tempting to consider that early endothelial and tumour cell alterations may be promoted by ET-1 produced by both cell types. Further work is required that will examine localised cellular gene expression of the endothelin system as well as its pro-invasive and angiogenic effects in breast cancer models.

Author Biography

Strinivasen Naidoo, Department of Therapeutics and Medicines Management, University of KwaZulu- Natal
Senior Lecturer; Therapeutics and Medicines Management, Faculty of Medicine, UKZN.


1. Cruz A. Endothelin-1, a regulator of angiogenesis in the chick chorioallantoic membrane. J Vasc Res. 2001;38:536–545. doi:10.1159/000051089, PMid:11740152.

2. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularisation in vivo. Am J Pathol. 2000;157:1703–1711. PMid:11073829, PMCid:1885730.

3. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2004;2(1):16. doi:10.1186/1479-5876-2-16, PMid:15165288, PMCid:436068

4. Salani D, Di Castro V, Nicotra MR, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol. 2000;157:1537–1547. PMid:11073813, PMCid:1885720.

5. Knowles J, Lozidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol. 2005;3(4):309–314. doi:10.2174/157016105774329462, PMid:16248773.

6. Stiles JD, Ostrow PT, Balos LL, et al. Correlation of endothelin-1 and transforming growth factor [beta]1 with malignancy and vascularity in human gliomas. J Neuropathol Exper Neurol. 1997;56(4):435–439. doi:10.1097/00005072-199704000-00012, PMid:9100674.

7. Shankar A, Loizidou M, Aliev G, et al. Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg. 1998;85(4):502–506. doi:10.1046/j.1365-2168.1998.00660.x, PMid:9607532.

8. Wülfing P, Kersting C, Tio J, et al. Characterization of expression of the endothelin-axis in breast cancer tissues and human breast cancer cell lines. Proc Am Assoc Cancer Res. 2004;45:708–709.

9. Wülfing P, Diallo R, Kersting C, et al. Endothelin-1, endothelin-A- and endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncol Rep. 2004;11:791–796.

10. Grimshaw MJ. Endothelins in breast tumour cell invasion. Cancer Lett. 2005;222(2):129–138. doi:10.1016/j.canlet.2004.08.029, PMid:15863261.

11. Wright JK, Botha JH, Naidoo S. Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis. Tumor Biol. 2008;29:130–136. doi:10.1159/000141918, PMid:18577888.

12. Olympus Soft Imaging Solutions GmbH. AnalySIS Pro. 5 ed. Munster; 1986–2006.

13. GraphPad Software. Instat. 3.10 ed. La Jolla; 1995–2009.

14. Wellstein A. Growth factor targeted and conventional therapy of breast cancer. Breast Cancer Res Treat. 1994;31:141–152. doi:10.1007/BF00666148, PMid:7533560.

15. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. A role for endothelin-2 and its receptors in breast tumour cell invasion. Cancer Res. 2004;64:2461–2468. doi:10.1158/0008-5472.CAN-03-1069, PMid:15059899.

16. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol. 2005;24(11):766–776. doi:10.1089/dna.2005.24.766, PMid:16274297.

17. Saijonmaa O, Nyman T, Fyhrquist F. Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem Biophys Res Comm. 1992;188(1):286–291. doi:10.1016/0006-291X(92)92382-8.